1
|
Shuba YM. Beyond Neuronal Heat Sensing: Diversity of TRPV1 Heat-Capsaicin Receptor-Channel Functions. Front Cell Neurosci 2021; 14:612480. [PMID: 33613196 PMCID: PMC7892457 DOI: 10.3389/fncel.2020.612480] [Citation(s) in RCA: 37] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2020] [Accepted: 12/23/2020] [Indexed: 12/20/2022] Open
Abstract
Transient receptor potential vanilloid 1 (TRPV1) is a calcium-permeable ion channel best known for its ability to be gated by the pungent constituent of red chili pepper, capsaicin, and related chemicals from the group of vanilloids as well as by noxious heat. As such, it is mostly expressed in sensory neurons to act as a detector of painful stimuli produced by pungent chemicals and high temperatures. Its activation is also sensitized by the numerous endogenous inflammatory mediators and second messengers, making it an important determinant of nociceptive signaling. Except for such signaling, though, neuronal TRPV1 activation may influence various organ functions by promoting the release of bioactive neuropeptides from sensory fiber innervation organs. However, TRPV1 is also found outside the sensory nervous system in which its activation and function is not that straightforward. Thus, TRPV1 expression is detected in skeletal muscle; in some types of smooth muscle; in epithelial and immune cells; and in adipocytes, where it can be activated by the combination of dietary vanilloids, endovanilloids, and pro-inflammatory factors while the intracellular calcium signaling that this initiates can regulate processes as diverse as muscle constriction, cell differentiation, and carcinogenesis. The purpose of the present review is to provide a clear-cut distinction between neurogenic TRPV1 effects in various tissues consequent to its activation in sensory nerve endings and non-neurogenic TRPV1 effects due to its expression in cell types other than sensory neurons.
Collapse
Affiliation(s)
- Yaroslav M Shuba
- Bogomoletz Institute of Physiology, National Academy of Sciences of Ukraine, Kyiv, Ukraine
| |
Collapse
|
2
|
Quallo T, Alkhatib O, Gentry C, Andersson DA, Bevan S. G protein βγ subunits inhibit TRPM3 ion channels in sensory neurons. eLife 2017; 6. [PMID: 28826490 PMCID: PMC5593501 DOI: 10.7554/elife.26138] [Citation(s) in RCA: 66] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2017] [Accepted: 07/24/2017] [Indexed: 02/07/2023] Open
Abstract
Transient receptor potential (TRP) ion channels in peripheral sensory neurons are functionally regulated by hydrolysis of the phosphoinositide PI(4,5)P2 and changes in the level of protein kinase mediated phosphorylation following activation of various G protein coupled receptors. We now show that the activity of TRPM3 expressed in mouse dorsal root ganglion (DRG) neurons is inhibited by agonists of the Gi-coupled µ opioid, GABA-B and NPY receptors. These agonist effects are mediated by direct inhibition of TRPM3 by Gβγ subunits, rather than by a canonical cAMP mediated mechanism. The activity of TRPM3 in DRG neurons is also negatively modulated by tonic, constitutive GPCR activity as TRPM3 responses can be potentiated by GPCR inverse agonists. GPCR regulation of TRPM3 is also seen in vivo where Gi/o GPCRs agonists inhibited and inverse agonists potentiated TRPM3 mediated nociceptive behavioural responses. DOI:http://dx.doi.org/10.7554/eLife.26138.001 TRPM3 belongs to a family of channel proteins that allow sodium and calcium ions to enter cells by forming pores in cell membranes. TRPM3 is found on the cell membranes of nerve cells; when ions flow into the nerves through the TRPM3 pores it triggers an electrical impulse. TRPM3 is responsible for helping us to detect heat, and mice without this protein find it difficult to sense painfully hot temperatures. Mice lacking TRPM3 also respond to other kinds of pain differently. Normally, a mouse with an injured paw becomes more sensitive to warm and hot temperatures, but this does not happen in mice that do not have TRPM3. When activated, other proteins called G-protein coupled receptors (or GPCRs for short) can make some members of this family of channel proteins more or less likely to open their pore. This in turn increases or decreases the flow of ions through the pore, respectively. Yet it was not clear if GPCRs also affect TRPM3 channels on the membranes of nerve cells. Quallo et al. have now discovered that “switching on” different GPCR proteins in sensory nerve cells from mice greatly reduces the flow of calcium ions though TRPM3 channels. The experiments made use of two pain-killing drugs, namely morphine and baclofen, and a molecule called neuropeptide Y to activate different GPCRs. GPCRs interact with a group of small proteins called G-proteins that, when activated by the receptor, split into two subunits, known as the α subunit and the βγ subunit. Once detached these subunits are free to act as messengers and interact with other proteins in the cell membrane. Quallo et al. found that TRPM3 is one of a small group of proteins that interact with the βγ subunits of the G-protein, which can explain how “switching on” GPCRs reduces the activity of TRPM3. Two independent studies by Dembla, Behrendt et al. and Badheka, Yudin et al. also report similar findings. There is currently a need to find more effective treatments for people suffering from long-term pain conditions and it has become clear that TRPM3 channels are involved in sensing both pain and temperature. These new findings show that drugs already used in the treatment of pain can dramatically change how TRPM3 works. These results might help scientists to find drugs that work in a similar way to dial down the activity of TRPM3 and to combat pain. Though first it will be important to confirm these new findings in human nerve cells. DOI:http://dx.doi.org/10.7554/eLife.26138.002
Collapse
Affiliation(s)
- Talisia Quallo
- Wolfson Centre for Age-Related Diseases, King's College London, London, United Kingdom
| | - Omar Alkhatib
- Wolfson Centre for Age-Related Diseases, King's College London, London, United Kingdom
| | - Clive Gentry
- Wolfson Centre for Age-Related Diseases, King's College London, London, United Kingdom
| | - David A Andersson
- Wolfson Centre for Age-Related Diseases, King's College London, London, United Kingdom
| | - Stuart Bevan
- Wolfson Centre for Age-Related Diseases, King's College London, London, United Kingdom
| |
Collapse
|
3
|
Nagy I, Friston D, Valente JS, Torres Perez JV, Andreou AP. Pharmacology of the capsaicin receptor, transient receptor potential vanilloid type-1 ion channel. PROGRESS IN DRUG RESEARCH. FORTSCHRITTE DER ARZNEIMITTELFORSCHUNG. PROGRES DES RECHERCHES PHARMACEUTIQUES 2014; 68:39-76. [PMID: 24941664 DOI: 10.1007/978-3-0348-0828-6_2] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
The capsaicin receptor, transient receptor potential vanilloid type 1 ion channel (TRPV1), has been identified as a polymodal transducer molecule on a sub-set of primary sensory neurons which responds to various stimuli including noxious heat (> -42 degrees C), protons and vanilloids such as capsaicin, the hot ingredient of chilli peppers. Subsequently, TRPV1 has been found indispensable for the development of burning pain and reflex hyperactivity associated with inflammation of peripheral tissues and viscera, respectively. Therefore, TRPV1 is regarded as a major target for the development of novel agents for the control of pain and visceral hyperreflexia in inflammatory conditions. Initial efforts to introduce agents acting on TRPV1 into clinics have been hampered by unexpected side-effects due to wider than expected expression in various tissues, as well as by the complex pharmacology, of TRPV1. However, it is believed that better understanding of the pharmacological properties of TRPV1 and specific targeting of tissues may eventually lead to the development of clinically useful agents. In order to assist better understanding of TRPV1 pharmacology, here we are giving a comprehensive account on the activation and inactivation mechanisms and the structure-function relationship of TRPV1.
Collapse
|
4
|
Czikora Á, Lizanecz E, Bakó P, Rutkai I, Ruzsnavszky F, Magyar J, Pórszász R, Kark T, Facskó A, Papp Z, Édes I, Tóth A. Structure-activity relationships of vanilloid receptor agonists for arteriolar TRPV1. Br J Pharmacol 2012; 165:1801-1812. [PMID: 21883148 DOI: 10.1111/j.1476-5381.2011.01645.x] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Abstract
BACKGROUND AND PURPOSE The transient receptor potential vanilloid 1 (TRPV1) plays a role in the activation of sensory neurons by various painful stimuli and is a therapeutic target. However, functional TRPV1 that affect microvascular diameter are also expressed in peripheral arteries and we attempted to characterize this receptor. EXPERIMENTAL APPROACH Sensory TRPV1 activation was measured in rats by use of an eye wiping assay. Arteriolar TRPV1-mediated smooth muscle specific responses (arteriolar diameter, changes in intracellular Ca(2+)) were determined in isolated, pressurized skeletal muscle arterioles obtained from the rat and wild-type or TRPV1(-/-) mice and in canine isolated smooth muscle cells. The vascular pharmacology of the TRPV1 agonists (potency, efficacy, kinetics of action and receptor desensitization) was determined in rat isolated skeletal muscle arteries. KEY RESULTS Capsaicin evoked a constrictor response in isolated arteries similar to that mediated by noradrenaline, this was absent in arteries from TRPV1 knockout mice and competitively inhibited by TRPV1 antagonist AMG9810. Capsaicin increased intracellular Ca(2+) in the arteriolar wall and in isolated smooth muscle cells. The TRPV1 agonists evoked similar vascular constrictions (MSK-195 and JYL-79) or were without effect (resiniferatoxin and JYL-273), although all increased the number of responses (sensory activation) in the eye wiping assay. Maximal doses of all agonists induced complete desensitization (tachyphylaxis) of arteriolar TRPV1 (with the exception of capsaicin). Responses to the partial agonist JYL-1511 suggested 10% TRPV1 activation is sufficient to evoke vascular tachyphylaxis without sensory activation. CONCLUSIONS AND IMPLICATIONS Arteriolar TRPV1 have different pharmacological properties from those located on sensory neurons in the rat.
Collapse
Affiliation(s)
- Á Czikora
- Division of Clinical Physiology, Institute of CardiologyDepartment of PhysiologyDepartment of Pharmacology and Pharmacotherapy, Institute of PharmacologyDepartment of OphthalmologyResearch Centre for Molecular Medicine, Medical and Health Science Center, University of Debrecen, Debrecen, Hungary
| | - E Lizanecz
- Division of Clinical Physiology, Institute of CardiologyDepartment of PhysiologyDepartment of Pharmacology and Pharmacotherapy, Institute of PharmacologyDepartment of OphthalmologyResearch Centre for Molecular Medicine, Medical and Health Science Center, University of Debrecen, Debrecen, Hungary
| | - P Bakó
- Division of Clinical Physiology, Institute of CardiologyDepartment of PhysiologyDepartment of Pharmacology and Pharmacotherapy, Institute of PharmacologyDepartment of OphthalmologyResearch Centre for Molecular Medicine, Medical and Health Science Center, University of Debrecen, Debrecen, Hungary
| | - I Rutkai
- Division of Clinical Physiology, Institute of CardiologyDepartment of PhysiologyDepartment of Pharmacology and Pharmacotherapy, Institute of PharmacologyDepartment of OphthalmologyResearch Centre for Molecular Medicine, Medical and Health Science Center, University of Debrecen, Debrecen, Hungary
| | - F Ruzsnavszky
- Division of Clinical Physiology, Institute of CardiologyDepartment of PhysiologyDepartment of Pharmacology and Pharmacotherapy, Institute of PharmacologyDepartment of OphthalmologyResearch Centre for Molecular Medicine, Medical and Health Science Center, University of Debrecen, Debrecen, Hungary
| | - J Magyar
- Division of Clinical Physiology, Institute of CardiologyDepartment of PhysiologyDepartment of Pharmacology and Pharmacotherapy, Institute of PharmacologyDepartment of OphthalmologyResearch Centre for Molecular Medicine, Medical and Health Science Center, University of Debrecen, Debrecen, Hungary
| | - R Pórszász
- Division of Clinical Physiology, Institute of CardiologyDepartment of PhysiologyDepartment of Pharmacology and Pharmacotherapy, Institute of PharmacologyDepartment of OphthalmologyResearch Centre for Molecular Medicine, Medical and Health Science Center, University of Debrecen, Debrecen, Hungary
| | - T Kark
- Division of Clinical Physiology, Institute of CardiologyDepartment of PhysiologyDepartment of Pharmacology and Pharmacotherapy, Institute of PharmacologyDepartment of OphthalmologyResearch Centre for Molecular Medicine, Medical and Health Science Center, University of Debrecen, Debrecen, Hungary
| | - A Facskó
- Division of Clinical Physiology, Institute of CardiologyDepartment of PhysiologyDepartment of Pharmacology and Pharmacotherapy, Institute of PharmacologyDepartment of OphthalmologyResearch Centre for Molecular Medicine, Medical and Health Science Center, University of Debrecen, Debrecen, Hungary
| | - Z Papp
- Division of Clinical Physiology, Institute of CardiologyDepartment of PhysiologyDepartment of Pharmacology and Pharmacotherapy, Institute of PharmacologyDepartment of OphthalmologyResearch Centre for Molecular Medicine, Medical and Health Science Center, University of Debrecen, Debrecen, Hungary
| | - I Édes
- Division of Clinical Physiology, Institute of CardiologyDepartment of PhysiologyDepartment of Pharmacology and Pharmacotherapy, Institute of PharmacologyDepartment of OphthalmologyResearch Centre for Molecular Medicine, Medical and Health Science Center, University of Debrecen, Debrecen, Hungary
| | - A Tóth
- Division of Clinical Physiology, Institute of CardiologyDepartment of PhysiologyDepartment of Pharmacology and Pharmacotherapy, Institute of PharmacologyDepartment of OphthalmologyResearch Centre for Molecular Medicine, Medical and Health Science Center, University of Debrecen, Debrecen, Hungary
| |
Collapse
|
5
|
Abstract
Phosphoinositides, especially phosphatidylinositol 4,5-bisphosphate [PtdIns(4,5)P(2)] are required for the activity of many different ion channels. This chapter will highlight various aspects of this paradigm, by discussing current knowledge on four different ion channel families: inwardly rectifying K(+) (Kir) channels, KCNQ voltage gated K(+) channels, voltage gated Ca(2+) (VGCC) channels and Transient Receptor Potential (TRP) channels. Our main focus is to discuss functional aspects of this regulation, i.e. how changes in the concentration of PtdIns(4,5)P(2) in the plasma membrane upon phospholipase C activation may modulate the activity of ion channels, and what are the major determinants of this regulation. We also discuss how channels act as coincidence detectors sensing phosphoinositide levels and other signalling molecules. We also briefly discuss the available methods to study phosphoinositide regulation of ion channels, and structural aspects of interaction of ion channel proteins with these phospholipids. Finally, in several cases the effect of PtdIns(4,5)P(2) is more complex than a simple dependence of ion channel activity on the lipid, and we will discuss some these complexities.
Collapse
Affiliation(s)
- Nikita Gamper
- Institute of Membrane and Systems Biology, Faculty of Biological Sciences, University of Leeds, LS2 9JT, Leeds, UK,
| | | |
Collapse
|